Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegargiminase,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : Erkim
Deal Size : Undisclosed
Deal Type : Agreement
Er-Kim, Polaris Ink Deal to Sell Pegargiminase for MPM in EMEA
Details : Under the agreement, Polaris will holds the rights for commercialization of ADI-PEG 20 (pegargiminase). It is being evaluated in late-satge for the treatment of malignant pleural mesothelioma
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
April 15, 2025
Lead Product(s) : Pegargiminase,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Erkim
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI-PEG 20 (pegylated arginine deiminase, pegargiminase) is designed to deplete the external supply of arginine, and is being investigated for Non-Alcoholic Steatohepatitis (NASH).
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 29, 2023
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI-PEG 20 (pegargiminase) ia arginie degrader, which is being evaluated in phase 2/3 clinical trials in combination with cisplatin & pemetrexed for the treatment of malignant pleural mesothelioma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 16, 2023
Lead Product(s) : Pegargiminase,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : Global Coalition for Adaptive Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI-PEG 20 (pegargiminase) is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed, which is investigated for glioblastoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Global Coalition for Adaptive Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Ifosfamide,Mesna
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 14, 2023
Lead Product(s) : Pegargiminase,Ifosfamide,Mesna
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Docetaxel,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADI-PEG 20 (pegargiminase) is an Arginine Degrader Enzyme drug candidate, which is currently being evaluating clinical trial studies with patients for the treatment of Leiomyosarcoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 12, 2023
Lead Product(s) : Pegargiminase,Docetaxel,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Gemcitabine,Docetaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 15, 2022
Lead Product(s) : Pegargiminase,Gemcitabine,Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : Pegargiminase,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable